<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381871</url>
  </required_header>
  <id_info>
    <org_study_id>GA&amp; COVID19</org_study_id>
    <nct_id>NCT04381871</nct_id>
  </id_info>
  <brief_title>Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients</brief_title>
  <acronym>GA&amp;COVID19</acronym>
  <official_title>Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Neelain University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Neelain University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among
      COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other
      half will receive placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized placebo controlled trial including COVID 19 seropositive patients will be treated
      with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in
      positive COVID 19 patients.

      Blood samples will be taken first at base line level, after two weeks and after the
      intervention after satisfying the inclusion and exclusion criteria. The main objective is to
      assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients.
      The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the
      effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two months</time_frame>
    <description>The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine viral load in each patient</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change of viral load from Baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>clinical improvement and hospital discharge</measure>
    <time_frame>from the date of assignment until the date of hospital discharge for the last assigned case, whichever comes first, assessed up to two months</time_frame>
    <description>Time of discharge from hospital after full recovery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be provided with pectin powder provided as one-gram-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acacia Senegal</intervention_name>
    <description>Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>Gum Arabic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pectin</intervention_name>
    <description>Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly
             diagnosed)

        Exclusion Criteria:

          -  Intubated patients on parental treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mustafa KM Nimeiri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Al Neelain University, Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moawia M Mukhtar, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Khartom , Institute of Endemic Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Babiker, PhD</last_name>
    <phone>+249912951517</phone>
    <email>rashat33@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shahenaz Satti, MSc</last_name>
    <phone>+249912204825</phone>
    <email>shahenazsatti@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Omdurman Teaching Hospital</name>
      <address>
        <city>Khartoum</city>
        <state>Omdurman</state>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jabra Hospital,</name>
      <address>
        <city>Khartoum</city>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <reference>
    <citation>Ali NE, Kaddam LA, Alkarib SY, Kaballo BG, Khalid SA, Higawee A, AbdElhabib A, AlaaAldeen A, Phillips AO, Saeed AM. Gum Arabic (Acacia Senegal) Augmented Total Antioxidant Capacity and Reduced C-Reactive Protein among Haemodialysis Patients in Phase II Trial. Int J Nephrol. 2020 Apr 9;2020:7214673. doi: 10.1155/2020/7214673. eCollection 2020.</citation>
    <PMID>32328307</PMID>
  </reference>
  <reference>
    <citation>Kamal E, Kaddam LA, Dahawi M, Osman M, Salih MA, Alagib A, Saeed A. Gum Arabic Fibers Decreased Inflammatory Markers and Disease Severity Score among Rheumatoid Arthritis Patients, Phase II Trial. Int J Rheumatol. 2018 Jul 5;2018:4197537. doi: 10.1155/2018/4197537. eCollection 2018.</citation>
    <PMID>30112005</PMID>
  </reference>
  <reference>
    <citation>Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620.</citation>
    <PMID>32287140</PMID>
  </reference>
  <reference>
    <citation>Ruscitti P, Berardicurti O, Iagnocco A, Giacomelli R. Cytokine storm syndrome in severe COVID-19. Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.</citation>
    <PMID>32376400</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Neelain University</investigator_affiliation>
    <investigator_full_name>Lamis Kaddam</investigator_full_name>
    <investigator_title>Dr.Lamis Kaddam</investigator_title>
  </responsible_party>
  <keyword>Gum Arabic</keyword>
  <keyword>Immunomodulator</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

